Soligenix, Inc. (SNGX) reported the results of a booster vaccination study using CiVax in non-human primates showing rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. CiVax is the company's heat stable subunit vaccine candidate for the prevention of COVID-19.
The company noted that, within one week of receiving booster, neutralizing antibody levels increased as much as 27-fold against the original and Delta strains. By three weeks, this increased up to 243-fold.
Shares of Soligenix were up 3% in pre-market trade on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.